Evaluation of the Long Term Safety, Tolerability and Efficacy of Two Dosing Regimens of Olokizumab (OKZ), in Subjects With Rheumatoid Arthritis (RA) Who Previously Completed 24 Weeks of Blinded Treatment in One of the Core Studies - CREDO 1, 2 or 3.; CRED

Prensa/medios de comunicación

Período2 oct. 2018

Cobertura de los medios

1

Cobertura de los medios

  • NombreEvaluation of the Long Term Safety, Tolerability and Efficacy of Two Dosing Regimens of Olokizumab (OKZ), in Subjects With Rheumatoid Arthritis (RA) Who Previously Completed 24 Weeks of Blinded Treatment in One of the Core Studies - CREDO 1, 2 or 3.; CRED
    Nombre/canal del medio de comunicaciónClinical Trials.gov
    Fecha2/10/18
    PersonasDiego Luis Saaibi Solano